All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
AACR 2017: Poster 2094/21 – ON150030 for treatment of R/R AML
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Monday 3rd April, a poster session titled “Growth Factor and Hormone Receptors as Therapeutic Targets” took place.
During this session, a poster (2094 /21) titled “Dual inhibition of FLT3 and Src pathways by ON150030, a type 1 inhibitor, as a novel strategy for relapsed and refractory AML therapy” by Helya Ghaffari and colleagues from the Icahn School of Medicine at Mount Sinai, New York City, was on display.
Quizartinib inhibits FLT3-ITD in Acute Myeloid Leukemia (AML). Quizartinib binds to the inactive form of FLT3 but fails to inhibit FLT3-ITD harboring D835 mutation. In this study, the authors investigated the efficacy of ON150030, a type 1 inhibitor, which binds to the active form of FLT3.
The key results were:
- Compared to quizartinib, ON150030 inhibited both wild-type and FLT3-D835Y
- ON150030 inhibited the growth of MV4-11 cells (FLT3-ITD positive AML cell line) harboring FLT3-ITD mutations
- Increasing dose of ON150030 in MV4-11 cells was associated with an inhibition of MAPK and PI3K/AKT pathways in these cells
- ON150030 reduces JAK independent phosphorylation of STAT5
In summary, ON15003 is a novel inhibitor with strong activity against SRC and FLT3 kinases. The authors highlighted that the distinct mode of action of ON15003 could be promising for therapy in AML.
References